Scholarlink

Study design <p>Investigator-initiated, single-arm, first-in-human pilot study.</p> Objectives <p>To evaluate the safety and feasibility of intramedullary administration of polymerized laminin in individuals with acute complete spinal cord injury (SCI).</p> Setting <p>Public and private hospitals in Brazil.</p> Methods <p>Eight patients with acute traumatic SCI classified as AIS A (C4–T12) were enrolled within days after injury (mean 2.3 days). Polymerized laminin was administered as a single intramedullary dose (1 µg/kg; total 55–80 µg). Patients were followed for 12 months using standardized neurological, laboratory, and neurophysiological assessments.</p> Results <p>Intramedullary administration was uneventful in all cases. No neurological deterioration or serious adverse events attributable to the intervention were observed. Mild laboratory abnormalities were transient and not associated with hepatic or renal toxicity. Three participants died during follow-up. Deaths were reviewed by the Brazilian National Research Ethics Commission (CONEP) and an external clinical consultant, and were not considered related to the intervention. Neurological improvement of at least two AIS grades was observed in six participants, including one who died after progressing to AIS C. Improvements in motor and/or somatosensory evoked potentials were observed in three patients.</p> Conclusions <p>Intramedullary administration of polymerized laminin was uneventful and appeared to be safe in this small and heterogeneous cohort. Although the study design does not allow conclusions regarding efficacy, it provides proof-of-concept for this therapeutic approach and justifies further evaluation in controlled clinical studies. The study was initiated in December 2016, prior to current requirements for prospective trial registration.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Intramedullary injection of polymerized laminin in acute traumatic spinal cord injury: a first-in-human pilot study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月4日

查看全文
  • Marco Aurelio B. Lima,
  • Karla Menezes,
  • Denise R. Xerez,
  • Bruno A. Côrtes,
  • João R. L. Menezes,
  • Gustavo S. Holanda,
  • Adriana D. Silva,
  • Eliel S. Leite,
  • Olavo B. Franco,
  • Marco Aurélio A. M. de Faria,
  • Arthur de Freitas Forte,
  • Livia V. Abreu,
  • Renata C. L. Lichtenberger,
  • Cíntia F. Santana,
  • Maurilio Rosa,
  • Aurélio V. Graça-Souza,
  • Álvaro U. C. Jorge,
  • Ana Cristina Franzoi,
  • Arthur S. Ferreira,
  • Rose M. Frajtag,
  • Tatiana Coelho‐Sampaio

摘要

Study design

Investigator-initiated, single-arm, first-in-human pilot study.

Objectives

To evaluate the safety and feasibility of intramedullary administration of polymerized laminin in individuals with acute complete spinal cord injury (SCI).

Setting

Public and private hospitals in Brazil.

Methods

Eight patients with acute traumatic SCI classified as AIS A (C4–T12) were enrolled within days after injury (mean 2.3 days). Polymerized laminin was administered as a single intramedullary dose (1 µg/kg; total 55–80 µg). Patients were followed for 12 months using standardized neurological, laboratory, and neurophysiological assessments.

Results

Intramedullary administration was uneventful in all cases. No neurological deterioration or serious adverse events attributable to the intervention were observed. Mild laboratory abnormalities were transient and not associated with hepatic or renal toxicity. Three participants died during follow-up. Deaths were reviewed by the Brazilian National Research Ethics Commission (CONEP) and an external clinical consultant, and were not considered related to the intervention. Neurological improvement of at least two AIS grades was observed in six participants, including one who died after progressing to AIS C. Improvements in motor and/or somatosensory evoked potentials were observed in three patients.

Conclusions

Intramedullary administration of polymerized laminin was uneventful and appeared to be safe in this small and heterogeneous cohort. Although the study design does not allow conclusions regarding efficacy, it provides proof-of-concept for this therapeutic approach and justifies further evaluation in controlled clinical studies. The study was initiated in December 2016, prior to current requirements for prospective trial registration.